Hip Osteoarthritis

Presentation Slides

Chinese Medicine Research Hub

Systematic Review

In people with hip osteoarthritis, at close to 8 weeks, acupuncture plus routine primary physician care may improve pain and function compared to routine primary physician care alone.

2018 Cochrane Database of Systematic Reviews Acupuncture for hip osteoarthritis
Manheimer E, Cheng K, Wieland LS, Shen X, Lao L, Guo M, Berman BM.

Chinese Medicine Research Hub

Randomised Controlled Trial

The daily use of avocado-soybean unsaponifiable-expanscience (ASU-E) reduces the progression of joint space narrowing in patients with hip osteoarthritis.

2013 Annals of the Rheumatic Diseases Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study
Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, Dougados M, Mazières B, Spector TD, Halhol H, Grouin JM, Lequesne M

Executive Summary

Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Hip Osteoarthritis" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.

Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Hip Osteoarthritis" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.

Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Hip Osteoarthritis" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.

A Systematic Review published in 2018 in the journal Cochrane Database of Systematic Reviews found that In people with hip osteoarthritis, at close to 8 weeks, acupuncture plus routine primary physician care may improve pain and function compared to routine primary physician care alone. Because acupuncture has previously been documented to have a low risk of adverse effects, and because arthritis patients seem to be accepting of acupuncture (Rao 1999), there seem to be few drawbacks to hip OA patients electing to receive acupuncture, other than the additional costs incurred. While some private health insurance plans cover much of the costs of acupuncture, it is not typically covered by governmental health plans, with some exceptions (NICE 2009). Thus, the out‐of‐pocket costs of the acupuncture will vary depending on an individual's health plan. Given the potential disability caused by OA of the hip and the few available treatments, acupuncture may be considered one treatment option, particularly among patients who are not yet ready for a joint replacement or who are unable to tolerate oral NSAIDs. However, patients should be informed that acupuncture probably has little or no effect in reducing pain or improving function relative to sham acupuncture. . Because there are currently no registered ongoing RCTs, this evidence base is unlikely to substantially change in the near future.

A Randomised Controlled Trial published in 2013 in the journal Annals of the Rheumatic Diseases found that The daily use of avocado-soybean unsaponifiable-expanscience (ASU-E) reduces the progression of joint space narrowing in patients with hip osteoarthritis. The conducted trial was a prospective, randomised, double-blind study with parallel groups under placebo control over three years. The participants included symptomatic hip osteoarthritis patients having experienced pain for a minimum of one year and featuring a joint space width (JSW) between 1 and 4 mm in the affected hip. Participants were assigned randomly to a daily intake of 300 mg ASU-E or a placebo. Annual pelvic radiographs in standing position were performed, with the primary focus on the change in JSW at the end of year three. Despite no significant difference in mean JSW loss between the ASU-E group and placebo, fewer progressors (patients with JSW loss of 0.5mm or more) were recorded in the ASU-E group, marking a 20% decrease compared to the placebo group. This indicates a potential therapeutic effect of ASU-E on the structural integrity of hip joints in osteoarthritis patients. However, clinical outcome comparisons did not yield any significant differences between the groups. The safety profile of ASU-E was determined to be excellent.

Moderation Tools

Topic